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Summary
 
The multidrug resistance protein 1 (
 
MRP1
 
) gene encodes a transporter protein that helps to
protect cells against xenobiotics. Elevated levels of MRP1 in tumor cells can result in active ex-
trusion of a wide range of (anticancer) drugs with different cellular targets, a phenomenon
called multidrug resistance (MDR). To explore the protective function of the mouse mrp1
protein during drug treatment, we investigated the toxicity caused by the anticancer drug eto-
poside-phosphate (ETOPOPHOS) in mice lacking the 
 
mrp1
 
 gene (
 
mrp1
 
2
 
/
 
2
 
 mice). We show
here that the lack of mrp1 protein results in increased etoposide-induced damage to the mucosa
of the oropharyngeal cavity and to the seminiferous tubules of the testis. The high concentra-
tions of mrp1 that we find in the basal layers of the oropharyngeal mucosa and in the basal
membrane of the Sertoli cells in the testis apparently protect wild-type mice against this tissue
damage. We also find drug-induced polyuria in 
 
mrp1
 
2
 
/
 
2
 
 mice, which correlates with the pres-
ence of mrp1 protein in the urinary collecting tubules, the major site of kidney water reabsorp-
tion. Our results indicate that specific inhibitors of MRP1 used to reverse MDR, in combina-
tion with carcinostatic drugs transported by MRP1, might lead to drug-induced mucositis,
(temporary) infertility, and diabetes insipidus.
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M
 
ultidrug resistance (MDR)
 
1
 
 of tumor cells is an ob-
stacle to successful anticancer treatment. In human
cancer cells, MDR can be caused by the enhanced drug ef-
flux mediated by two members of the ATP-binding cas-
sette (ABC) superfamily of transporter proteins, the MDR
gene 1 (MDR1) P-glycoprotein (Pgp; reference 1) and
MDR protein 1 (MRP1 [2–6]). Pgp can transport hydro-
phobic amphipathic compounds like anthracyclines, 
 
Vinca
 
alkaloids, epipodophyllotoxins, and taxanes in unmodified
form. MRP1 can transport negatively charged conjugated
hydrophilic compounds with a large hydrophobic moiety
as well as hydrophobic amphipathic compounds. Both
transporter genes were identified because of their overex-
pression in MDR tumor cell lines, and it is likely that both
proteins contribute to the (intrinsic or acquired) resistance
against drugs used in cancer therapy.
MRP1 can act as a glucuronide- or glutathione 
 
S
 
-conju-
gate (GS-X) pump or multispecific organic anion trans-
porter (MOAT [7–13]). Five other members of the MRP
family have been found thus far (14): canalicular (c)MOAT
or MRP2 (15, 16), MRP3, MRP4, MRP5, and MRP6. It
is not yet known whether MRP2–6 play a role in MDR.
To elucidate the physiological functions of the MDR-
conferring proteins, mutant mice have been generated
lacking Pgp (17, 18) or mrp1 protein (19, 20). These
knockout mice provide a useful pharmacological tool to
study the effects of complete blockade of these transporters.
 
1
 
Abbreviations used in this paper:
 
 cMOAT and cmoat, human and mouse
canalicular multispecific organic anion transporter, respectively; ETOPO-
PHOS, etoposide-phosphate; FeNa, fractional excretion of sodium;
GFR, glomerular filtration rate; GS-X, glutathione 
 
S
 
-conjugate; LTC
 
4
 
,
leukotriene C
 
4
 
; MDR, multidrug resistance; MDR1 and mdr1, human
and mouse multidrug resistance gene 1, respectively; MRP1 and mrp1,
human and mouse multidrug resistance protein 1, respectively; Pgp, P-gly-
coprotein; RFI, renal failure index; U
 
Cr
 
 and P
 
Cr
 
, urine and plasma creati-
nine.
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mrp1
 
2
 
/
 
2
 
 Mice
 
In addition, these animals are proving helpful in testing the
specificity and effectiveness of MDR reversal agents.
Analyses of mice lacking mdr1a Pgp established an im-
portant role for this Pgp in the blood–brain barrier, as it
protects the brain against entry of xenobiotics. This trans-
porter is also important in the intestine, where it actively
excretes xenobiotics from the bloodstream into the intesti-
nal lumen, and limits the entry of these Pgp substrates from
the intestinal lumen (17, 18, 21). Mice homozygous for an
 
mrp1
 
 null allele, 
 
mrp1
 
2
 
/
 
2
 
, have an impaired response to an
arachidonic acid–induced inflammatory stimulus. This is
most likely due to a decreased secretion of leukotriene C
 
4
 
(LTC
 
4
 
) from mast cells, macrophages, and eosinophilic and
basophilic granulocytes (19). We showed that mrp1 actively
transports GS-X substrates across the mouse erythrocyte
membrane, and mediates drug (e.g., etoposide, vincristine)
resistance to bone marrow–derived mast cells in vitro. Fur-
thermore, we and others showed that the 
 
mrp1
 
2
 
/
 
2
 
 mice are
hypersensitive to the anticancer drug etoposide, resulting in
loss of body weight and mortality (19, 20). However, the
reason for this hypersensitivity remained unknown.
We show here that mrp1 is present in the basal epithelial
layer of the tongue and mucosal layer of the cheek, in the
basal plasma membrane of the Sertoli cells, and in the kid-
ney urinary collecting duct cells. We also demonstrate that
the etoposide treatment of 
 
mrp1
 
2
 
/
 
2
 
 mice leads to damage
of the mucosal layer of the tongue and cheek, and to inhi-
bition of spermatogenesis. Our data indicate that an ac-
quired diabetes insipidus and oropharyngeal toxicity are
important elements in the etoposide hypersensitivity of the
 
mrp1
 
2
 
/
 
2
 
 mice, and might become clinically relevant if eto-
poside is combined with an MRP1 blocker.
 
Materials and Methods
 
Animals.
 
The animals used were mrp1-deficient (
 
mrp1
 
2
 
/
 
2
 
)
mice, generated by gene targeting in embryonic stem cells as de-
scribed by Wijnholds et al. (19). Control and mutant mice were
on the genetic background (129/Ola)/FVB (50%/50%). All ani-
mals were housed in constant temperature rooms with a 12-h
light/12-h dark cycle, and were fed a pelleted chow diet (Hope
Farms B.V., Woerden, The Netherlands) and were given acidi-
fied water ad libitum. Mouse handling and experimental proce-
dures were conducted in accordance with institutional guidelines
for animal care and use.
 
Drug Sensitivity.
 
Etoposide-phosphate (100 mg effective eto-
poside, ETOPOPHOS
 
Ò
 
; Bristol Myers-Squibb Pharmaceuticals,
Princeton, NJ) was dissolved in sterile 0.9% NaCl to obtain a
stock solution of 20 mg/ml. Concentrations were adjusted to in-
ject intravenously 5–7 
 
m
 
l/g body wt (40–140 mg/kg) in a tail
vein of male mice (11–13 wk old) lightly anesthetized with di-
ethyl ether. Mice were weighed and observed daily for a period
of 2 wk. Lethal toxicity occurred between days 2 and 13 after in-
jection. In experiments where urine and feces were separately
collected, mice were kept in type M/1 stainless steel metabolic
cages (Ruco Metaalindustrie Nederland B.V., Valkenswaard, The
Netherlands), and specimens were collected during time intervals
of 0–2, 2–4, and 4–6 d.
 
Histological Analysis.
 
Tissues were obtained by dissection of
mice (
 
n
 
 
 
5
 
 5 per genotype) after lethal anesthesia with diethyl
ether, fixed in ethanol/acetic acid/formaldehyde in 0.9% NaCl
(40:5:10:45, vol/vol/vol/vol), embedded in paraffin, sectioned at
5 
 
m
 
m, and stained with hematoxylin and eosin.
 
Immunohistochemical Analysis.
 
Cryostat sections were cut 4
 
m
 
m thick, air-dried overnight, and fixed in acetone for 10 min at
room temperature. The slides were incubated with normal rabbit
serum for 10 min and incubated with the mAb MRPr1 (5 
 
m
 
g/ml)
for 1 h at room temperature (22). All reagents were diluted in
PBS containing 1% (wt/vol) BSA (PBS/BSA). Sections were
stained by the biotin-streptavidin immunoperoxidase method, us-
ing biotinylated rabbit anti–rat IgG (1:100; Dakopatts A/S, Glos-
trup, Denmark) and avidin/biotin complex (1:200; Dakopatts A/S).
Bound peroxidase was developed with 0.02% H
 
2
 
O
 
2
 
 and 0.5 g/li-
ter 3,3
 
9
 
-diaminobenzidine tetrahydrochloride (Sigma Chemical
Co., St. Louis, MO). All slides were counterstained with hema-
toxylin and mounted. Negative controls included both the omis-
sion of the first step and substitution of the primary antibody by
isotype-matched nonspecific control antibodies.
 
Clinical Chemistry and Hematology.
 
Hemoglobin, hematocrit, and
erythrocyte, leucocyte, and thrombocyte counts were determined
in heparinized blood on a Coulter counter (Coulter Corp., Mi-
ami, FL). Total protein, sodium, creatinine, urea, and glucose
concentrations in plasma, and urinary glucose, creatinine, sodium,
and potassium concentrations were determined on an analyzer ac-
cording to the instructions of the manufacturer (model 911; Hita-
chi Instruments, Inc., San Jose, CA).
 
Measurement of Renal Function.
 
Glomerular filtration rate (GFR)
was calculated as the clearance of creatinine according to the for-
mula, GFR 
 
5
 
 (U
 
Cr
 
 
 
3 
 
U
 
vol
 
)/P
 
Cr
 
, where U
 
Cr
 
 and P
 
Cr
 
 are the urine
and plasma creatinine concentrations, respectively, and U
 
vol
 
 is
urine volume. Fractional excretion of sodium (FeNa) was calcu-
lated according to the formula, FeNa 
 
5
 
 (U
 
Na
 
 
 
3 
 
P
 
Cr
 
) 
 
3 
 
100/
(P
 
Na
 
 
 
3 
 
U
 
Cr
 
), where U
 
Na
 
 and P
 
Na
 
 are the urine and plasma sodium
concentrations, respectively. The renal failure index (RFI) was
calculated according to the formula, RFI 
 
5
 
 U
 
Na
 
/(U
 
Cr
 
/P
 
Cr
 
). Also
calculated were blood urea nitrogen (BUN)/P
 
Cr
 
 and U
 
Cr
 
/P
 
Cr
 
.
 
Statistical Evaluation.
 
The results are presented as means 
 
6
 
SE. The difference between groups was evaluated with the Stu-
dent’s 
 
t
 
 test.
 
Table 1.
 
ETOPOPHOS Toxicity in Male Wild-type and
mrp1-deficient Mice (11–13 wk old)
 
ETOPOPHOS
dose
Survival of mice
Wild-type
 
mrp1
 
2
 
/
 
2
 
(mg/kg)
 
40 — 3/3
60 3/3 6/6
80 3/3 11/11
100 3/3 1/3
110 — 0/3
115 — 0/3
120 8/8 0/3
140 0/3 0/3
The number of surviving animals per group at each intravenous ETO-
POPHOS dose is listed. 
 
mrp1
 
2
 
/
 
2
 
 mice show increased sensitivity to
ETOPOPHOS; 
 
P
 
 
 
, 
 
0.01. 
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Results
 
Sensitivity to ETOPOPHOS.
 
It has been shown that
mice lacking a functional 
 
mrp1
 
 gene are hypersensitive to
etoposide, resulting in loss of body weight and lethality (19,
20). The cause of the loss of body weight and lethality was
unclear, since we did not find differences in etoposide tis-
sue distribution, the area under the plasma concentration–
time curve for the drug, or in hematological parameters, or
in biliary, fecal, or urinary excretion of radiolabeled etopo-
side (19). The 
 
mrp1
 
2/2 
 
mice are also hypersensitive to the
pro-drug ETOPOPHOS (Table 1; references 19 and 20).
After 7 d, the wild-type mice retained 91 
 
6 
 
2% of body
weight (
 
n
 
 
 
5
 
 15; 30.0 
 
6
 
 0.6 g at day 0), whereas the mutant
mice that survived retained 74 
 
6
 
 2% (
 
P
 
 
 
, 
 
0.01) of body
weight (
 
n
 
 
 
5
 
 14; 29.8 
 
6
 
 0.4 g at day 0), after a single intra-
venous dose of 100 mg/kg of ETOPOPHOS. The symp-
toms observed in the mutant mice after drug treatment in-
cluded a partial closure of the eyes and a soft testis, but no
clear gross abnormalities were observed in the appearance
or size of the liver, kidney, intestinal tract, spleen, lung,
heart, brain, or other tissues. Mice that survived for 7 d (14
out of 15 mice) were more active than wild-type mice,
showed a mucus substance around the mouth, and showed
alopecia specifically around the mouth, chin, and forelegs,
possibly due to the observed abnormally active polishing.
Not before 4 d (19, 20) but after 7 d of drug treatment, the
number of white blood cells dropped to a significantly
lower level in drug-treated wild-type as well as 
 
mrp1
 
2
 
/
 
2
 
mice compared with drug-naive controls, whereas the
number of thrombocytes increased (see Table 2). However,
in microscopic analysis of tissues, we did not find symptoms
Table 2. Plasma and Urinary Variables in ETOPOPHOS-treated and Naive Mice
Drug-naive Drug-treated
Wild-type mrp12/2 Wild-type mrp12/2
Hematocrit 0.45 6 0.01 0.43 6 0.01 0.40 6 0.02 0.42 6 0.03
Leukocytes, 109/liter 9.3 6 0.5** 9.5 6 0.7‡‡ 5.8 6 0.6 2.5 6 0.4§§
Thrombocytes, 109/liter 48 6 5* 165 6 76‡ 369 6 142 696 6 148
Plasma values
Protein, g/liter 57 6 1 56 6 1‡ 55 6 2 71 6 9§
Creatinine, mmol/liter 33 6 2 37 6 1‡ 43 6 4 49 6 4
Sodium, mmol/liter 138 6 2* 139 6 1‡ 147 6 4 150 6 4
Urea, mmol/liter 8.9 6 0.4 9.7 6 0.5‡ 11.0 6 1.2 15.7 6 2.0
Glucose, mmol/liter 4.7 6 0.4 4.9 6 0.5 4.0 6 1.2 4.2 6 0.4
Urine values
Vol (d1–2), ml/48 h 2.4 6 0.3** 2.7 6 0.5‡‡‡ 4.4 6 0.5 7.2 6 0.6§
Vol (d3–4), ml/48 h 3.2 6 0.5 3.7 6 0.7‡ 1.8 6 0.4 6.6 6 0.9§§
Vol (d5–6), ml/48 h 3.1 6 0.5 3.8 6 0.6‡‡ 2.3 6 0.5 7.5 6 0.4§§§
Creatinine, mmol/liter 7.8 6 1.0 6.5 6 0.8‡‡ 8.6 6 1.4 2.3 6 0.4§§
mmol/48 h 21.0 6 1.8 21.8 6 2.0 16.2 6 2.4 16.8 6 2.0
Glucose, mmol/liter 7.0 6 1.2 6.0 6 1.7‡ 10.2 6 3.1 1.0 6 0.5§
mmol/48 h 17.9 6 1.7 18.3 6 3.5‡ 17.1 6 2.8 6.6 6 3.0§
Sodium, mmol/liter 241 6 26 176 6 20‡‡ 167 6 40 56 6 9§
mmol/48 h 663 6 62** 602 6 68 267 6 60 387 6 48
Potassium, mmol/liter 358 6 31 287 6 32‡‡ 294 6 52 96 6 16§§
mmol/48 h 1018 6 111* 987 6 106 547 6 75 685 6 72
FeNa, % 0.74 6 0.03* 0.73 6 0.03 0.46 6 0.09§ 0.81 6 0.07
RFI, mmol/liter 1.0 6 0.0* 1.0 6 0.0 0.7 6 0.1§ 1.2 6 0.1
GFR, ml/48 h 655 6 65* 598 6 65 399 6 62 365 6 90
UCr/PCr 242 6 31 175 6 19‡‡ 228 6 50 52 6 16§
BUN/PCr 273 6 9 262 6 12 258 6 8 318 6 30
Plasma values 7 d after ETOPOPHOS administration (100 mg/kg). Urinary values are for the day 5–6 sample. Statistical significance is indicated as
follows: *drug-treated versus drug-naive wild-type; ‡drug-treated versus drug-naive mrp12/2; §drug-treated mrp12/2 versus drug-treated wild-type
mice. A single symbol (e.g.,*) denotes P , 0.05; a double symbol (e.g.,**) P , 0.01; a triple symbol (e.g.,***) P , 0.001. In all comparisons, n 5 6.
BUN, Blood urea nitrogen; d, day.800 Drug-induced Mucositis, Testicular Damage, and Polyuria in mrp12/2 Mice
of gross infection or occult bleeding. The mucus excretion
from the mouth indicated a possible defect in the oropha-
ryngeal cavity. To determine the cause of the loss of body
weight after drug treatment, we examined parameters for
dehydration, food uptake, and fecal and urinary excretion.
Drug-induced Hypotonic Polyuria in ETOPOPHOS-treated
mrp12/2 Mice. The food uptake and fecal excretion dur-
ing 7 d were not significantly different between drug-
treated mutant and wild-type mice (food uptake: 22 6 3
and 19 6 3 g; fecal excretion: 11 6 1 and 8 6 1 g, mutant
versus wild-type mice, respectively; n 5 6). However,
drug-treated mice tended to become dehydrated, as indi-
cated by the data presented in Table 2. Plasma sodium, cre-
atinine, and urea were modestly increased in drug-treated
mice, and this increase was significant at P , 0.05 in the
mrp12/2 mice. Plasma protein was increased as well in the
knockout mice. The hematocrit and mean cell volumes did
not differ significantly between drug-treated and -naive an-
imals.
Without drug treatment, the total 48-h urine volumes
were similar in wild-type and mutant mice. After drug
treatment, the mutant mice excreted a markedly larger
urine volume than the wild-type mice, indicative of a
drug-induced acquired polyuria. Values for urinary sodium,
potassium, creatinine, and glucose in 48-h urine collected
on days 5 and 6 were normal and similar in drug-naive
wild-type and mutant mice. Compared with the drug-
treated wild-type and drug-naive mice, the concentrations
of sodium, potassium, and creatinine in the urine (mmol/
liter) of the drug-treated mutant mice were significantly
lower, but the total excretion of these electrolytes (mmol/
48 h) did not differ significantly, indicative of dilute urine.
The drug-treated mutant mice excreted significantly less
glucose in the urine, indicating that glucose reabsorption
by the mutant kidney was functional. We also tested
whether drug-naive old female mice (14 mo of age) had
developed a spontaneous polyuria, but no significant differ-
ences were detected between wild-type and mutant mice
(3.1 6 0.8 and 3.9 6 0.6 ml/48 h, respectively). The
FeNa, GFR, and RFI (Table 2) indicate a modest drug-
induced renal failure in wild-type but not in mutant mice.
However, the drug-treated mutant mice acquired hypo-
tonic polyuria.
Oropharyngeal Morphology of ETOPOPHOS-treated mrp12/2
Mice. To investigate the abnormal mucus production in
the mouth, we performed a histological examination on
sections through the head. Staining with hematoxylin and
eosin revealed that the epithelial layer of the mutant tongue
is heavily damaged, with a disappearance of all tongue pa-
pillae (Fig. 1, A–D). In addition, the mucosal layer of the
cheek is distorted (Fig. 1, E and F). Some mice show skin
infections around the mouth, a beginning parodontitis, and
infections on the surface of the tongue without signs of
deep penetration of bacteria into the tissue. Wild-type
mice treated with the drug do not show a changed mor-
phology or disappearance of the papillae or a distortion of
the mucosal layer of the cheek, and do not show oropha-
ryngeal bacterial infections. No microscopic abnormalities
were observed in the salivary or other excretory glands, the
muscular layer of the tongue, the palatum, the eye, the
nose area, the brain, or other parts of the head. Also, no ab-
normalities were observed in the mucosal layer of the
esophagus, or in the small or large intestines. However, the
stomach was empty in most of the mutant animals, and a
regeneration of crypts was occurring specifically around the
pylorus (Fig. 1, G and H). These findings show that the
mutant mice treated with ETOPOPHOS suffer from
oropharyngeal toxicity, and that mrp1 protects drug-sensi-
tive epithelial layers in the oropharyngeal cavity of wild-
type mice.
Testicular Morphology of ETOPOPHOS-treated mrp12/2
Mice. We reported previously that mice lacking mrp1 are
viable and fertile for at least 1 yr under normal animal facil-
ity conditions, with no obvious difference in litter size, in-
dicating that these mice do not show abnormal breeding
characteristics. However, the testis of drug-treated mutant
mice looked abnormal, and we therefore examined the
weight of the testis. Testis from drug-naive wild-type and
mutant mice did not differ significantly in weight (187 6
15 and 204 6 7 mg in seven mice, respectively). Drug
treatment resulted in a lower testis weight for wild-type as
well as mutant mice (143 6 9 and 106 6 3 mg in six mice,
P , 0.05 and P , 0.001, respectively). Weight loss differed
significantly between drug-treated mutant and wild-type
mice (P , 0.01).
Spermatogenesis is a tightly organized differentiation
process in the seminiferous tubules that occurs according to
a cycle of subsequent stages, with specific cell associations
at different cross sections of the testicular tubules (the sper-
matogenic cycle). Histological sections stained with hema-
toxylin and eosin indicated that the testis of drug-treated
mutant mice showed largely distorted spermatogenesis with
no signs of meiotic divisions (Fig. 2, A and B), and an in-
creased number of prematurely released round germ cells,
including many spermatids, with very few spermatozoa in
the epididymis (Fig. 2, C and D). The testis of drug-treated
wild-type mice showed a partially distorted spermatogene-
sis, but meiotic divisions still occurred and the epididymis
contained many spermatozoa and several prematurely re-
leased round germ cells. These findings indicate that mrp1
could play a direct protective role in the blood–testis bar-
rier.
Figure 1. Hematoxylin and eosin–stained paraffin sections of tissues from ETOPOPHOS-treated wild-type and mrp1-deficient mice. Wild-type (A,
C, E, and G) and mrp1-deficient (B, D, F, and H) mice 7 d after ETOPOPHOS administration. (A and B) Sections of the oropharyngeal cavity through
the tongue, molars, and palatum showing a degeneration of the mucosal layers of the tongue and cheek (B). (C and D) Higher magnification showing at801 Wijnholds et al.
the bottom the tongue and mucosal layer. (E and F) Higher magnification of A and B showing at the bottom the tongue and mucosal layer, and above it
the mucosal layer of the cheek. (G and H) Sections through the stomach pyloric region. The dark staining reveals a regeneration of crypts (H). Same
magnification in A and B (bar, 200 mm), and in C–H (bar, 100 mm).802 Drug-induced Mucositis, Testicular Damage, and Polyuria in mrp12/2 Mice
Further histological examination indicated that the thy-
mus was degenerated upon drug treatment in both geno-
types, and that the mutant bone marrow was rich in cells
and showed in a few cases megakaryocytosis. The liver,
kidney, lung, bronchi, heart, pancreas, esophagus, intestinal
tract, urinary bladder, adrenal gland, thyroid, bone and car-
tilage, salivary glands, secondary sex organs, mammary
glands, spleen, and lymph nodes showed no significant dif-
ferences between drug-naive and drug-treated animals.
mrp1 in the Tongue, Testis, and Kidney. In humans, MRP1
protein is detected in sweat and sebaceous glands of the
skin, in the ducts of the salivary glands and pancreas, in ep-
ithelia of the esophagus, colon, stomach, lung, and tonsil,
in muscular layers of the large intestine, heart, smooth and
skeletal muscle, in the cortex of the adrenal glands, in islets
of Langerhans of the pancreas, and in Leydig and Sertoli
cells of the testis, and weak immunoreactivity has been re-
ported for the tubules of the kidney (22). No protein has
been detected in the capillary endothelial cells. In situ
RNA hybridization has shown that mrp1 RNA is present
in some of the seminiferous tubules of the testis (23).
To correlate the observed drug-induced hypotonic poly-
uria and the damage in the oropharyngeal cavity and the
testis with mrp1 protein location, we stained sections with
the mAb MRPr1 directed against an NH2-terminal part of
the human MRP1 (22). As negative controls, we used mice
lacking mrp1 (19), and isotype control antibodies.
Mouse mrp1 is present in high amounts in the mucosal
layer of the tongue, whereas very low levels were detected
in the muscular layer (Fig. 3, A and B). High levels were
also found in the mucosal layers of the cheek (Fig. 3, C and
D), esophagus (Fig. 3, E and F), and lung (Fig. 3, G and
H). Interestingly, mrp1 mainly resides in the basolateral
membranes of the mouse lung epithelium, rather than in
subapical vesicles as in human bronchial epithelium (22).
Immunostaining revealed high levels of mrp1 protein in
the epithelial layers of the limb of Henle and the urinary
collecting ducts in the marrow and cortex of the wild-type
kidney, whereas the glomeruli and the proximal convo-
luted tubules showed no immunoreactivity (Fig. 4, A–D).
In the testis, the Leydig cells in the interstitial tissue out-
side of the seminiferous tubules, and the basal plasma mem-
brane but not the apical or the lateral membranes of all the
Sertoli cells in the seminiferous tubules contain mrp1 (Fig.
4, E–H). The tight junctions in between neighboring Ser-
toli cells, unlike other polarized cells, are located near the
basal plasma membrane, on the adluminal side of the sper-
matogonia (24), explaining the absence of mrp1 in the ad-
luminal part of lateral membranes. No staining is observed
in the endothelial layer of the blood vessels in the testis, a
position where Pgp is known to reside (25, 26). The loca-
tion of the drug pump mrp1 in the basal plasma membrane
of the Sertoli cells supports a protective function in sper-
matogenesis, since Sertoli cells form a Sertoli–Sertoli cell
Figure 2. Hematoxylin and eosin–stained paraffin sections of testis and epididymis from ETOPOPHOS-treated wild-type and mrp1-deficient mice.
Wild-type (A and C) and mrp1-deficient (B and D) mice 7 d after ETOPOPHOS administration. (A and B) Sections of the testis showing vacuoles and
disrupted spermatogenesis (B). (C and D) Sections of the epididymis showing reduced numbers of intact spermatids in the lumen (D). Bar, 100 mm.803 Wijnholds et al.
Figure 3. mrp1 staining of frozen sections of drug-naive wild-type and mrp1-deficient tissues. Sections were counterstained with hematoxylin. Wild-
type (A, C, E, and G) and mrp1-deficient (B, D, F, and H) mice. (A and B) Sections of the tongue showing mrp1 staining in the mucosal layer (A). (C
and D) Sections of the mucosal layer of the cheek. (E and F) Sections of the esophagus. (G and H) Sections of the lung. Bar, 50 mm.804 Drug-induced Mucositis, Testicular Damage, and Polyuria in mrp12/2 Mice
Figure 4. mrp1 staining of frozen sections of drug-naive wild-type and mrp1-deficient tissues. Sections were counterstained with hematoxylin. Wild-
type (A, C, E, and G) and mrp1-deficient (B, D, F, and H) mice. (A–D) Sections of the kidney showing mrp1 staining in the limb of Henle and urinary805 Wijnholds et al.
barrier, the so-called blood–testis barrier, against xenobiot-
ics (24, 27).
Discussion
Our data show that the cellular drug exporter mrp1 pro-
tects mice against oropharyngeal and testicular damage by
the anticancer drug etoposide. This protective function will
most likely extend to several xenobiotics, carcinogens, and
(anti)cancer drugs, and possibly also to chemical substances
reducing fertility. Like the mdr1a Pgp (17, 18), mrp1 ap-
pears to be an important element in the defense against po-
tentially harmful compounds in the diet and toxins released
during bacterial or fungal infections. The aggravating effect
of mrp1 deficiency becomes pronounced after drug treat-
ment or an inflammatory stimulus (19), indicating that
mrp1 is involved in ancient (cellular drug extrusion) as well
as more sophisticated (cellular LTC4 extrusion) mechanisms
of cellular protection. As the function and tissue distribu-
tion of murine mrp1 and human MRP1 are similar, we ex-
pect our mouse results to be relevant for drug-induced
damage in humans.
Is mrp1 of Importance for the Protection of Kidney Function?
The drug-induced hypotonic polyuria in mrp1-deficient
mice could be either renal or due to excessive drinking
caused by the oral mucositis. Since the drug-treated mutant
mice show symptoms of dehydration with relatively high
plasma levels of protein, sodium, creatinine, and urea, it is
unlikely that primary polydipsia can explain the polyuria,
although it may contribute. Therefore, we focused on the
kidney. The data indicate either a reduced responsiveness
of the urinary collecting ducts to vasopressin, or a reduced
effectiveness or plasma level of vasopressin. A water-depri-
vation test did not help to distinguish between a nephro-
genic or central diabetes insipidus, since the majority of
drug-treated mutant mice did not survive (four out of
seven mice; data not shown) a 20-h water deprivation 48 h
after drug administration. Since mrp1 is not expressed in
the magnocellular neurons of the anterior hypothalamus
which secrete vasopressin (22), there is no reason why the
osmoregulatory and vasopressin-producing cells would be
more sensitive to drug in the mrp1 mutant than in wild-
type mice. Therefore it is unlikely that the polyuria is
caused by central diabetes insipidus.
The urinary collecting ducts are the site of water reab-
sorption regulated by vasopressin, whereas passive water
transport occurs in the proximal convoluted tubules and in
the descending limb of Henle. The ascending limb of
Henle and the distal convoluted tubes are largely imperme-
able to water. The permeability of the urinary collecting
ducts to water in the absence of vasopressin is low but can
be enhanced in the presence of vasopressin (28). mrp1 is
present in the basolateral membranes of these collecting
ducts. Even though we did not observe histological abnor-
malities in these ducts, we propose that etoposide treatment
of mrp1 mutant mice causes cell damage or persistent subtle
changes in the presence or function of vasopressin receptors
in the basolateral membrane of the collecting ducts, leading
to reduced renal tubular responsiveness to vasopressin. This
interpretation implies that the polyuria is caused, at least in
part, by drug-induced acquired nephrogenic diabetes insip-
idus.
mrp1 Plays a Major Role in the Protection against Chemother-
apy-induced Mucositis. Oropharyngeal mucosal injury due
to cytotoxic agents is caused by damage to stem cells in the
basal epithelium, where these cells are subsequently de-
pleted, paving the way for infections and inflammation
(29). Mucositis is a common, painful condition which oc-
curs in the majority of patients who receive high-dose che-
motherapy for the treatment of cancer. In fact, mucositis is
the dose-limiting toxicity for many combinations of anti-
cancer drugs clinically in use (29, 30). The factors deter-
mining oropharyngeal toxicity have remained largely un-
known (29). Our data show that the drug transporter mrp1
is one of these factors. The absence of this protein results in
a severe disruption of the mucosal layer of the tongue and
cheek during a high-dose etoposide treatment.
What Might Be the Cause of Death of mrp1 Mutant Mice
during the Etoposide Mortality Test? The mrp12/2 mice are
killed at lower etoposide doses than wild-type mice (19,
20), but the cause of this hypersensitivity has remained un-
clear, as we found no evidence for increased drug exposure
or bone marrow depression in our initial studies (19). We now
find a significant decrease in leukocytes 7 d after etoposide
administration (Table 2). Combined with the oropharyn-
geal damage and the decreased inflammatory response due
to defective LTC4 secretion (19), this could compromise
the ability of mrp12/2 mice to cope with opportunistic in-
fections. The hemoconcentration observed might also
jeopardize survival. However, it is possible that there are
additional drug targets protected by mrp1 that contribute
to the hypersensitivity of the mrp12/2 mice and that remain
to be found.
We attribute the etoposide-induced toxicities in the
mrp12/2 mice to the absence of a functional mrp1 drug
transporter in the affected cells. An alternate explanation
might be the presence of an unnoticed subtle defect leading
indirectly to the toxicities described. This seems unlikely,
since the etoposide hypersensitivity was observed in two
independently derived mrp12/2 mouse lines (19, 20). It is
also unlikely to be a secondary effect of altered drug phar-
macokinetics, as there were no differences between wild-
type and mrp12/2 mice (19). Moreover, the toxicities de-
scribed in this study affect cells which normally contain
mrp1. However, the definitive experiment might come
from transgenic mrp12/2 mice in which the etoposide sensi-
collecting ducts, and the absence of staining in the glomeruli and proximal convoluted tubules (C and D). (E–H) Sections of the testis showing mrp1
staining in the Leydig and Sertoli cells. (G and H) Higher magnification of E and F. Same magnification in A–D (bar, 100 mm), in E and F (bar, 50 mm),
and in G and H (bar, 50 mm).806 Drug-induced Mucositis, Testicular Damage, and Polyuria in mrp12/2 Mice
tivity is rescued by overexpressing a wild-type mrp1 gene
under the control of a Sertoli cell–specific, oropharyngeal
or renal collecting tubular epithelium–specific promoter.
Our data show that some tissues are mainly protected
against etoposide by the drug transporter mrp1. Other tis-
sues, e.g., epithelia of esophagus and intestines (21) and en-
dothelia of blood brain capillaries (17, 18), might be mainly
protected against etoposide by one or several Pgps or other
members of the drug-transporter family. The identification
and subsequent ablation of each of these drug transporters
in mice might reveal tissues uniquely or redundantly pro-
tected by drug transporters. Indeed, mice which lack the
three drug transporters mdr1a, mdr1b, and mrp1 are viable
and fertile but show higher sensitivity to etoposide than
mice lacking only one of the transporters (J.Wijnholds,
A.H. Schinkel, and P. Borst, unpublished data).
Implications for Treatment of Patients with Carcinostatic Drugs
Transported by MRP1. Mucosal protectants which lower
the rate of basal cell proliferation lower the susceptibility of
the epithelium to drugs (29) and might be clinically useful
in reducing the oral toxic side effects, but this needs to be
proven. Our finding that mrp1 plays an important role in
the protection against drug-induced oral injury could po-
tentially be clinically exploited. If it were possible to tran-
siently elevate levels of mrp1 in the basal epithelial layers of
the tongue and cheek by drugs, this might reduce the sus-
ceptibility of the epithelium to anticancer drugs.
Significance of mrp1 in the Protective Role of the Blood–Testis
Barrier. We show here that mrp1 is present in the basal
plasma membrane of all Sertoli cells. The etoposide-induced
impairment of spermatogenesis and premature release of
spermatogenic cells in mrp1-deficient testis indicates that
mrp1 plays an important role in the protection of the Ser-
toli–germ cell communication network (24, 27, 31). The
seminiferous tubules of the testis contain two cell types:
germ cells, which constitute the male contribution to the
reproductive cycle, and Sertoli cells, which support the
growth and differentiation of germ cells. Sertoli cells abut
onto the basal lamina of the tubules, and are joined near
their bases by tight or occluding junctions, to create a per-
meability barrier between the extratubular and intratubular
compartments. The blood–testis barrier is formed by the
tight junctions as well as by the body of the Sertoli cells
(24). A proper cell number ratio between maturing germ
cells and Sertoli cells is essential for proper spermatogenesis,
and disruption of this complex network might result in
permanently reduced function.
High levels of mrp1, and MRP1 (22), are also detected
in the Leydig (or interstitial) cells which are grouped in the
supportive connective tissue between the seminiferous
tubules next to blood vessels and nerves. No histological
differences were detected in the Leydig cells after drug
treatment. The seminiferous tubules are partially under
hormonal control by the Leydig cells. Therefore, we can-
not exclude that damage of these cells contributes to the
drug-induced reduction of spermatogenesis.
In humans, persistent fertility problems can occur after
chemotherapy or consumption of food toxins or after med-
ications (32). We hypothesize that MRP1 deficiency or
malfunction might play a role in reduced viable sperm
numbers. Lowered levels of MRP1 in the Sertoli–Sertoli
cell barrier would lead to decreased efflux of infertility-
inducing MRP1 substrates (such as etoposide) from the Ser-
toli cells. Interestingly, MDR1 Pgp is present in the capillary
endothelium (25, 26) and might play a role in the blood–
testis barrier as well. In conclusion, our results using the
mrp1 mutant mice imply that the clinical use of inhibitors
of MRP1 (drug reversal agents) in combination with che-
motherapy increases the risk of reduction in fertility.
What Is the Physiological Role of mrp1 Localized in the Basal
or Basolateral Plasma Membranes of Polarized Cells? Our dem-
onstration that mrp1 resides in the basolateral membranes of
the lung epithelium and in the basal plasma membrane of
the Sertoli cells extends previous work showing the baso-
lateral localization of human MRP1 in transfected kidney
cells (33) and of murine mrp1 in liver (34). This contrasts
with the apical location of other drug pumps, such as the
MDR1 Pgp or the GS-X pump cMOAT (or MRP2 [16,
25]). The presence of mrp1 in the basal but not the apical
plasma membrane of Sertoli cells makes sense, as it helps to
protect not only the Sertoli cells themselves, but also the
other cells in the seminiferous tubules from xenotoxins. In
fact, we expect mrp1 to be an essential component of the
Sertoli–Sertoli cell barrier, in a similar way as the MDR1-
type Pgp acts as a guardian of the blood–brain barrier (17,
18). In addition, mrp1 might help to clear metabolic waste
products (e.g., hormone metabolites) from the seminiferous
tubule. Our results also indicate that the drug-clearing role
of mrp1 may be more important than previously thought.
Drug-clearing by cmoat, mdr1a, and mdr1b has always
been rather obvious, as these transporters are located in api-
cal membranes and directly secrete into luminal spaces. The
basolateral location of mrp1 seems less suitable for this pur-
pose and more appropriate for the secretion of useful mole-
cules, or for the retrieval of valuable metabolites, e.g., from
urine. However, our results with oral mucosa and testis
show that removal of toxins from cells into the interstitial
fluid may be effective in protecting vital epithelial struc-
tures against damage. For instance, in the lung, mrp1 in the
epithelium could assist in the clearance of toxins coming
from the luminal or interstitial fluid (back) into the intersti-
tial fluid. In other polarized epithelia flanking lumens,
mrp1 may have similar protective functions.
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